Skip to main content

Advertisement

SpringerLink
Log in

Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population

  • Original research article
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

Hepatitis C virus infectivity and replication efficiency appears to be dependent on the lipid content and organization of the plasma membrane of the host cell, as well as of the intracellular membranous web. As there is increasing awareness of a role played by the efflux pump ABCB1 (p-glycoprotein, P-gp) in lipid homeostasis, its function could be a determinant of chronic HCV infection. The aim of the present study was to examine and compare the distribution of common ABCB1 genotypes in patients with chronic HCV infection (n = 168), hyperlipidemic patients (n = 168) and a control group (n = 173), all from Greece.

Methods

Participants were genotyped for the ABCB1 2677G>T/A and 3435C>T polymorphisms with previously reported PCR-RFLP methods. Genotype and allele frequency distributions were compared between the three groups with the χ2 test of independence.

Results

The ABCB1 2677GG (ancestral) genotypes were significantly over-represented in patients with chronic hepatitis C compared to controls (39.3% vs. 26.6%, p = 0.015 according to the dominant model). A similar result was obtained when hyperlipidemic patients were compared to controls (45.2% vs. 26.6%, p < 0.001 according to the dominant model). Comparison of ABCB1 3435C>T genotype and allele distributions provided similar but not as significant differences. Genotype and allele distributions for both ABCB1 2677G>T/A and 3435C>T were very similar between HCV patients and hyperlipidemic patients.

Conclusion

Our findings imply an influence of ABCB1 polymorphisms on HCV infectivity, possibly through an effect on lipid homeostasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107–15.

    Article  CAS  PubMed  Google Scholar 

  3. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450–6.

    Article  CAS  PubMed  Google Scholar 

  4. Hu GR, Zheng BX, Liu ZF. Association between TGFB1 915G/C polymorphism and susceptibility to chronic hepatitis C virus infection: a meta-analysis. Biomed Rep 2014;2:239–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis 2010;9:8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Schäfer G, Blumenthal MJ, Katz AA. Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses 2015;7:2592–617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol 2015;62:763–70.

    Article  CAS  PubMed  Google Scholar 

  8. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins — impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013;5:1292–324.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Thakral S, Ghoshal K. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther 2015;15:142–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Haid S, Pietschmann T, Pécheur E-I. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem 2009;284:17657–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, et al. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 2008;82:5715–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003;200:553–60.

    Article  CAS  PubMed  Google Scholar 

  14. Debry P, Nash EA, Neklason DW, Metherall JE. Role of multidrug resistance P-glycoproteins in cholesterol esterification. J Biol Chem 1997;272:1026–31.

    Article  CAS  PubMed  Google Scholar 

  15. Un K, Sakai-Kato K, Oshima Y, Kawanishi T, Okuda H. Intracellular trafficking mechanism, from intracellular uptake to extracellular efflux, for phospholipid/cholesterol liposomes. Biomaterials 2012;33:8131–41.

    Article  CAS  PubMed  Google Scholar 

  16. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12:437–450.

    Article  CAS  PubMed  Google Scholar 

  17. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Owen A, Chandler B, Back DJ. The implications of P-glycoprotein in HIV: friend or foe. Fundam Clin Pharmacol 2005;19:283–96.

    Article  CAS  PubMed  Google Scholar 

  19. Kedmi M, Maayan S, Cohen SB, Hauzi M, Rund D. MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease. AIDS Patient Care STDS 2007;21:653–8.

    Article  PubMed  Google Scholar 

  20. Zhang L, Yesupriya A, Hu DJ, Chang MH, Dowling NF, Ned RM, et al. Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in Mexican Americans. Hepatology 2012;55:1008–18.

    Article  CAS  PubMed  Google Scholar 

  21. Dickens D, Owen A, Alfirevic A, Pirmohamed M. ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. Pharmacogenet Genomics 2013;23:314–23.

    Article  CAS  PubMed  Google Scholar 

  22. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009;1794:860–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, et al. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res 2014;74:598–608.

    Article  CAS  PubMed  Google Scholar 

  24. Sakurai A, Onishi Y, Hirano H, Seigneuret M, Obanayama K, Kim G, et al. Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms ofhuman ABC transporter ABCB1 (P glycoprotein/MDR1). Biochemistry 2007;46:7678–7693.

    Article  CAS  PubMed  Google Scholar 

  25. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein. Trends Biochem Sci 2000;25:1–6.

    Article  CAS  PubMed  Google Scholar 

  26. Rodrigues AC, Hirata MH, Hirata RD. Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. Pharmacogenomics 2009;10:1007–16.

    Article  CAS  PubMed  Google Scholar 

  27. Tempestilli M, Elisei F, Cimini E, D’Avolio A, Grassi G, Nicastri E, et al. Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. J Antimicrob Chemother 2014;69:1760–6.

    Article  CAS  PubMed  Google Scholar 

  28. Rodrigues AC, Rebecchi IM, Bertolami MC, Faludi AA, Hirata MH, Hirata RD. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 2005;38:1389–97.

    Article  CAS  PubMed  Google Scholar 

  29. Taegtmeyer AB, Breen JB, Smith J, Rogers P, Kullak-Ublick GA, Yacoub MH, et al. Effect of ABCB1 genotype on pre- and post-cardiac transplantation plasma lipid concentrations. J Cardiovasc Transl Res 2011;4:304–12.

    Article  PubMed  Google Scholar 

  30. Shabana MF, Mishriki AA, Issac MS, Bakhoum SW. Do MDR1 SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Mol Diagn Ther 2013;17:299–309.

    Article  CAS  PubMed  Google Scholar 

  31. Wang H, Perry JW, Lauring AS, Neddermann P, De Francesco R, Tai AW. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking. Gastroenterology 2014;146:1373–85.

    Article  CAS  PubMed  Google Scholar 

  32. Kusuma A, Romero-Brey I, Berger C, Colpitts CC, Boldanova T, Engelmann M, et al. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication via blockage of membranous web formation. Hepatology 2015 [Epub ahead of print].

  33. Rivero W, Rosso CN, Gentile E, Cuestas M, Tiribelli C, Oubiña JR, et al. Dissimilar expression of multidrug resistance mdr1 and bcrp by the replication of hepatitis C virus: role of the nonstructural 5A protein. J Viral Hepat 2013;20:e127–30.

    Article  Google Scholar 

  34. Banerji S, Ngo M, Lane CF, Robinson CA, Minogue S, Ridgway ND. Oxysterol binding protein-dependent activation of sphingomyelin synthesis in the golgi apparatus requires phosphatidylinositol 4-kinase IIα. Mol Biol Cell 2010;21:4141–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, et al. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. Cell Microbiol 2008;10:606–17.

    Article  CAS  PubMed  Google Scholar 

  36. Finnegan CM, Rawat SS, Cho EH, Guiffre DL, Lockett S, Merrill Jr. AH, et al. Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion. J Virol 2007;81:5294–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bottova I, Hehl AB, Stefanić S, Fabriàs G, Casas J, Schraner E, et al. Host cell P-glycoprotein is essential for cholesterol uptake and replication of Toxoplasma gondii. J Biol Sci 2009;284:17438–48.

    CAS  Google Scholar 

  38. Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, et al. Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection. PLoS One 2014;9:e92140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep 2011;63:808–14.

    Article  CAS  PubMed  Google Scholar 

  40. Sipeky C, Csongei V, Jaromi L, Safrany E, Maasz A, Takacs I, et al. Genetic variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian population samples with a review of the literature. Drug Metab Pharmacokinet 2011;26:206–15.

    Article  CAS  PubMed  Google Scholar 

  41. Naumovska Z, Nestorovska AK, Sterjev Z, Filipce A, Dimovski A, Suturkova LJ. Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphisms in macedonian population. Prilozi 2014;35:121–34.

    Article  PubMed  Google Scholar 

  42. Ayaz G, Batar B, Kanigur G, Guven M, Onaran I, Karadag B, et al. The association of MDR1 C3435T and G2677T/A polymorphisms with plasma platelet-activating factor levels and coronary artery disease risk in Turkish population. Gene 2013;527:301–5.

    Article  CAS  PubMed  Google Scholar 

  43. Ulzurrun E, Stephens C, Ruiz-Cabello F, Robles-Diaz M, Saenz-López P, Hallal H, et al. Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. PLoS One 2014;9:e94675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 2007;8:703–12.

    Article  CAS  PubMed  Google Scholar 

  45. Jeannesson E, Siest G, Bastien B, Albertini L, Aslanidis C, Schmitz G, et al. Association of ABCB1 gene polymorphisms with plasma lipid and apolipopro-tein concentrations in the STANISLAS cohort. Clin Chim Acta 2009;403:198–202.

    Article  CAS  PubMed  Google Scholar 

  46. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169–74.

    Article  CAS  PubMed  Google Scholar 

  47. Cizmarikova M, Podracka L, Klimcakova L, Habalova V, Boor A, Mojzis J, et al. MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results. Med Sci Monit 2015;21:59–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Westerlund M, Belin AC, Anvret A, Hakansson A, Nissbrandt H, Lind C, et al. Association of a polymorphism in the ABCB1 gene with Parkinson’s disease. Parkinsonism Relat Disord 2009;15:422–4.

    Article  PubMed  Google Scholar 

  49. Neuvonen AM, Palo JU, Sajantila A. Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users. Int J Legal Med 2011;125:265–9.

    Article  PubMed  Google Scholar 

  50. Youssef DM, Attia TA, El-Shal AS, Abduelometty FA. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids. Gene 2013;530:201–7.

    Article  CAS  PubMed  Google Scholar 

  51. Kassogue Y, Dehbi H, Nassereddine S, Quachouh M, Nadifi S. Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco. DNA Cell Biol 2013;32:582–8.

    Article  CAS  PubMed  Google Scholar 

  52. Oliveira E, Pereira R, Amorim A, McLeod H, Prata MJ. Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics 2009;10:1413–22.

    Article  PubMed  Google Scholar 

  53. Allabi AC, Horsmans Y, Issaoui B, Gala JL. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 2005;61:97–102.

    Article  CAS  PubMed  Google Scholar 

  54. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003;13:89–95.

    Article  CAS  PubMed  Google Scholar 

  55. Correia C, Santos P, Coutinho AM, Vicente AM. Characterization of pharmacogenetically relevant CYP2D6 and ABCB1 gene polymorphisms in a Portuguese population sample. Cell Biochem Funct 2009;27:251–5.

    Article  CAS  PubMed  Google Scholar 

  56. Hilli J, Rane A, Lundgren S, Bertilsson L, Laine K. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundam Clin Pharmacol 2007;21:379–86.

    Article  CAS  PubMed  Google Scholar 

  57. Yen-Revollo JL, Van Booven DJ, Peters EJ, Hoskins JM, Engen RM, Kannall HD, et al. Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J 2009;9:373–9.

    Article  CAS  PubMed  Google Scholar 

  58. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics 2011;12:1663–70.

    Article  CAS  PubMed  Google Scholar 

  59. Bonyadi M, Gholizadeh M, Soltan-Ali M. MDR1 C3435T polymorphism associated with the development of clinical features in Behçet’s disease in Iranian Azeri Turkish patients. Int J Dermatol 2014;53:1235–40.

    Article  CAS  PubMed  Google Scholar 

  60. Khedri A, Nejat-Shokouhi A, Salek R, Esmaeili H, Mokhtarifar A, Entezari Heravi R, et al. Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep 2011;38:2939–43.

    Article  CAS  PubMed  Google Scholar 

  61. Shalia KK, Shah VK, Pawar P, Divekar SS, Payannavar S. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response. Indian Heart J 2013;65:158–67.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001;358:383–4.

    Article  CAS  PubMed  Google Scholar 

  63. Jeong C, Di Rienzo A. Adaptations to local environments in modern human populations. Curr Opin Genet Dev 2014;29:1–8.

    Article  CAS  PubMed  Google Scholar 

  64. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 2004;13: 783–97.

    Article  CAS  PubMed  Google Scholar 

  65. Wang H, Ding K, Zhang Y, Jin L, Kullo IJ, He F. Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenet Genomics 2007;17:667–78.

    Article  CAS  PubMed  Google Scholar 

  66. Timucin M, Alagozlu H, Ozdemir S, Ozdemir O. Association between ABCB1 (MDR1) gene polymorphism and unresponsiveness combined therapy in chronic Hepatitis C virus. Hepat Mon 2013;13:e7522.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013;210:1109–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo SI, Waked I. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol Int 2015;9:251–7.

    Article  PubMed  Google Scholar 

  69. Kaczor MP, Seczyńska M, Szczeklik W, Sanak M. IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: systematic review of its prevalence in chronic hepatitis C patients and general population frequency. Pharmacol Rep 2015;67:260–6.

    Article  CAS  PubMed  Google Scholar 

  70. Manry J, Laval G, Patin E, Fornarino S, Itan Y, Fumagalli M, et al. Evolutionary genetic dissection of human interferons. J Exp Med 2011;208:2747–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Emma Gbandi, Antonis Goulas & Athanasia Panderi

  2. Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece

    Vassilios Sevastianos

  3. Evgenidion Hospital, Liver Research Unit of Athens University, Athens, Greece

    Stephanos Hadziyannis

  4. 2nd Academic Department of Internal Medicine, Hippokration Hospital of Athens, Athens, Greece

    John Koskinas

  5. Department of Gastroenterology, Athens University Medical School, Laikon General Hospital of Athens, Athens, Greece

    George Papatheodoridis & Panagiota Ioannidou

  6. 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Themistoklis Vasiliadis

  7. 1st Propedeutic Department of Internal Medicine, AHEPA Hospital, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Dimitrios Agapakis & Andreas Protopapas

  8. 2nd Department of Gastroenterology, Evangelismos General Hospital of Athens, Athens, Greece

    George Zacharakis

  9. 4th Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Hippokration General Hospital, Thessaloniki, Greece

    Emmanuil Sinakos

  10. Hepatology Service, Social Security Foundation, Athens, Greece

    Sotiris Koutsounas

  11. 1st Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece

    Georgios Germanidis

Authors
  1. Emma Gbandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonis Goulas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vassilios Sevastianos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephanos Hadziyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Athanasia Panderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John Koskinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. George Papatheodoridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Themistoklis Vasiliadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dimitrios Agapakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Andreas Protopapas
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Panagiota Ioannidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. George Zacharakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emmanuil Sinakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sotiris Koutsounas
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Georgios Germanidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonis Goulas.

Supplementary data

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gbandi, E., Goulas, A., Sevastianos, V. et al. Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. Pharmacol. Rep 68, 476–482 (2016). https://doi.org/10.1016/j.pharep.2015.10.009

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2015.10.009

Keywords

Search

Navigation